Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* 30-75 years of age~* less than 1% fluctuation in HbA1c over 3 months~* women must be on contraception~* HbA1c 6-9%~* willingness to sign approved consent form~Exclusion Criteria:~* Nursing mothers, pregnant women (excluded by a negative pregnancy test).~* Subjects requiring insulin therapy (\>20 units/day) and can not be converted to sulfonylurea therapy without loss of diabetes control.~* Patients with a history of drug or alcohol dependence in the last 5 years~* Patients with pre-existing cardiovascular disease including coronary artery disease, heart attack, heart failure, abnormal heart rhythms, structural abnormalities and valve disease, peripheral vascular disease and uncontrolled high blood pressure.~* Patients with a history of high cholesterol requiring therapy.~* Patients with severe systemic disease other than diabetes which has as a recognized complication neuropathy~* Patients currently taking drugs which act on the blood vessels (for example for hypertension)~* Patients taking antidepressants, or other drugs or medications known to interfere with the uptake or metabolism of catecholamines (stress hormones)~* Patients with poor renal function or have significant liver disease~* Patients with a history of previous kidney, pancreas or cardiac transplantation.~* Patients with a history of severe hypoglycemia which required the assistance of a third party or ketoacidosis requiring hospital admission within the last 3 months.~* Patients with lung disease for example resulting from chronic obstructive airways disease.~* Patients with abnormal thyroid function tests.~* Patients having taken other systemic investigational drugs (especially for neuropathy) or initiating a new or experimental insulin delivery device within 3 months of starting the study.~* Patients with a history of allergic reactions to multiple drugs or biological products.~* Obese patients (BMI greater than 35).~* Patients who refuse to sign the informed consent.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).